Precision oncology matches each patient with the therapy most likely to work, based on the molecular profile of their tumor. For molecular labs, that means turning somatic NGS data into reliable, actionable results: detecting SNVs, indels and CNVs, and assessing genomic signatures such as HRD, MSI and TMB that guide treatment decisions.
In this section, we share our latest articles on precision oncology: case studies from labs using SeqOne for somatic analysis, scientific insights on biomarkers like homologous recombination deficiency, and updates on how our platform helps teams deliver faster, clinically validated cancer reports.

GermVar PGx, the first module of SeqOne Preventive Genomics, supports laboratories with pharmacogenomic analysis inside the germline workflow, from star-allele calling to the guideline recommendations their experts review and report.

Valencia’s General University Hospital brought HRD testing in-house with Agilent and SeqOne. A 30-case study showed matching classifications vs. commercial assays, fewer inconclusive results, and turnaround cut from ~20 to 6-7 days.

SomaHRD v2 reaches 97.1% concordance with Myriad MyChoice CDx and a PFS hazard ratio of 0.23, with a 4.8% non-conclusive rate and results in 41 minutes.

Rewatch our webinar with Uppsala University Hospital: how one lab unified short-read, long-read, and array workflows on a single platform, and how transparent AI ranks variants so the geneticist stays in control.